Elixinol Wellness Ltd · ASX:EXL
Elixinol Wellness — Investor Presentation (March 2021)
18 slides from Elixinol Wellness's investor presentation, Mar 16, 2021
Slide 1: Investor Presentation Pack and Investor Briefing to be held Today
ASX Announcement 16 March 2021 Investor Presentation Pack and Investor Briefing to be held Today Elixinol Global Limited (Elixinol or the Company) (ASX:EXL; OTCQB:ELLXF) is pleased to invite investors to attend a special briefing today whereby Elixinol’s Global CEO and Executive Director, Mr Oliver
Slide 2: Key effects of the Proposed Transaction and contacts
The following sets out some key effects to the Company as a result of the Proposed Transaction proceeding: This document was authorised to be given to the ASX by the Board of the Company. Investor relations please contact: Ron Dufficy, Global Chief Financial Officer ron.dufficy@elixinolglobal.com Me
Slide 3: About Elixinol / About CannaCare
About Elixinol Elixinol Global Limited (ASX:EXL; OTCQB:ELLXF) is a global leader in the hemp industry, innovating, marketing and selling hemp derived nutraceutical, cosmetic and food products. The Company’s simplified business model is focusing on: ● In the Americas, innovating, marketing and sellin
Slide 4: Proposed acquisition of CannaCare Health to create a leading Pan-European CBD business
Proposed CannaCare Acquisition – Investor Update – 15 March 2021 ASX:EXL | OCTQB:ELLXF Proposed acquisition of CannaCare Health to create a leading Pan-European CBD business 15 March 2021 Kind of Amazing Kind of Amazing
Slide 5: Disclaimer
Proposed CannaCare Acquisition – Investor Update – 15 March 2021 Disclaimer This presentation contains summary way from anyone acting or refraining from financial condition, results of operations which may not be reasonable, and are information about Elixinol Global Limited acting as a result of thi
Slide 6: Our Vision Our Mission
Proposed CannaCare Acquisition – Investor Update – 15 March 2021 Elixinol CBD Our Vision Building a global, hemp derived, health elixinolSkin CBD and wellness consumer products business. Our Mission Hemp Foods Australia Making a positive contribution to people’s health, wellness and the planet throu
Slide 7: Transaction summary
Proposed CannaCare Acquisition – Investor Update – 15 March 2021 Transaction summary Elixinol plans to acquire leading German-based CBD business, CannaCare, to accelerate its vision of becoming a global, hemp-derived health and wellness consumer products business. • CannaCare’s CANOBO brand is the l
Slide 8: German CBD market is highly attractive
Proposed CannaCare Acquisition – Investor Update – 15 March 2021 German CBD market is highly attractive1 CannaCare presents an opportunity to take a significant share of Europe’s fastest growing CBD market. European CBD Markets Size (US$m)1 #1 Positive regulatory developments as the European Court o
Slide 9: CannaCare overview
Proposed CannaCare Acquisition – Investor Update – 15 March 2021 CannaCare overview CannaCare presents an opportunity to take a significant share of Europe’s fastest growing CBD market. • Established 2018, • Extensive product • CANOBO #1 • CANOBO first • Capital light • Investment in new • Strict qu
Slide 10: CannaCare distribution and routes-to-market
Proposed CannaCare Acquisition – Investor Update – 15 March 2021 CannaCare distribution and routes-to-market CannaCare enjoys a dominant position in traditional retail with particularly strong penetration in the drugstore channel (~42% market share 1) and pharmacies. Pharmacy/Drugstores E-Commerce H
Slide 11: Key people
Proposed CannaCare Acquisition – Investor Update – 15 March 2021 Key people FRANK OTTO OLIVER HAIST Strategy Partner & Shareholder Managing Director Serial founder in the media industry L’Oréal – Group Key Account Manager FMCG Founder and investor of many successful Philips – International Head of S
Slide 12: Synergies and growth outlook
Proposed CannaCare Acquisition – Investor Update – 15 March 2021 Synergies and growth outlook An acquisition of CannaCare will deliver Elixinol immediate material scale in Germany, while creating significant long-term value through a high growth market trend, identified cost synergies and potential
Slide 13: Key terms and funding
Proposed CannaCare Acquisition – Investor Update – 15 March 2021 Key terms and funding Earn-out structure de-risks the transaction and limits downside, while enhancing upside potential and incentive alignment. Key terms Purchase Upfront • €9m total upfront consideration to acquire 100% of CannaCare,
Slide 14: Timetable
Proposed CannaCare Acquisition – Investor Update – 15 March 2021 Timetable Event Date Despatch of Notice Of Meeting to shareholders Thursday, 15 April 2021 (including Independent Expert’s Report) Annual General Meeting Monday, 17 May 2021 Targeted transaction completion Monday, 5 July 2021 Issue of
Slide 15: Summary: accelerating the path to profitability
Proposed CannaCare Acquisition – Investor Update – 15 March 2021 Summary: accelerating the path to profitability The proposed CannaCare acquisition accelerates Elixinol’s vision of becoming a global, hemp derived health and wellness consumer products business. Fast market entry and delivers immediat
Slide 16: Q&A
Proposed CannaCare Acquisition – Investor Update – 15 March 2021 Q&A Kind of Amazing 12
Slide 17: Appendix
Proposed CannaCare Acquisition – Investor Update – 15 March 2021 Appendix The following sets out some key effects to the Company as a result of the Proposed Transaction proceeding: 1 Elixinol Group financial statements for year ended 31 December 2020 (audited). Annual EBITDA excludes asset impairmen
Slide 18: For more information
Proposed CannaCare Acquisition – Investor Update – 15 March 2021 For more information For investor relations please contact: For media please contact: Ron Dufficy, Global Chief Financial Officer Cherie Hartley, IR Department ron.dufficy@elixinolglobal.com cherie.hartley@irdepartment.com.au Kind of A
Elixinol Wellness — Investor Presentation (March 2021) on 6ix